Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 1

Status

Completed 18Unknown 6Terminated 6Recruiting 5Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 1275Carcinoma, Non-Small-Cell Lung 783Neoplasms 767Colorectal Neoplasms 755Carcinoma, Hepatocellular 579Stomach Neoplasms 578Prostatic Neoplasms 501Lung Neoplasms 461Pancreatic Neoplasms 416Rectal Neoplasms 331Recurrence 312Neoplasm Metastasis 305Leukemia, Myeloid, Acute 289Multiple Myeloma 281Colonic Neoplasms 280Lymphoma 273Uterine Cervical Neoplasms 269Esophageal Neoplasms 267Ovarian Neoplasms 261Head and Neck Neoplasms 246Melanoma 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 209Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 184Nasopharyngeal Carcinoma 180Lymphoma, Non-Hodgkin 173Leukemia 173Liver Neoplasms 163Glioblastoma 158Urinary Bladder Neoplasms 153

Interventions

Everolimus 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Interventional × Advanced Malignancies × Clear all
NCT04671875 2024-03-13

A Clinical Study of MIL93 in Solid Tumors.

Beijing Mabworks Biotech Co., Ltd.

Phase 1 Unknown
228 enrolled

Advanced Malignancies

NCT04916119 2022-09-16

Study of IBI323 in Patients With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
322 enrolled

Advanced Malignancies

NCT04085185 2022-09-14

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Unknown
268 enrolled

Advanced Malignancies

NCT05024305 2022-03-09

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Shandong TheraWisdom Biopharma Co., Ltd.

Phase 1 Unknown
81 enrolled

Advanced Malignancies

NCT04340427 2020-07-01

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown
50 enrolled

Advanced Malignancies

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown
35 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡